skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Disposition of /sup 14/C-acetohydroxamic acid and /sup 14/C-acetamide in the rat

Journal Article · · Drug Metab. Dispos.; (United States)
OSTI ID:5765777

Acetohydroxamic acid (AHA) has been identified as a potential agent for the treatment of infection-induced staghorn renal calculi in patients. The pharmacokinetics and disposition of /sup 14/C-acetamide have been evaluated in rats following iv and oral administration. The results of these experiments suggest that, following oral administration to rats, AHA is absorbed very rapidly from the gastrointestinal tract and is metabolized to acetamide and CO/sub 2/. Approximately 50-56% of the iv dose and 40-49% of the oral dose of /sup 14/C-AHA is excreted in the urine, suggesting a significant nonrenal elimination pathway for AHA and metabolite(s). Administration of /sup 14/C-acetamide to rats revealed that the compound is predominantly eliminated via the renal route, accounting for 68% of the administered radioactive dose. However, approximately 30% of the dose in the case of both AHA and acetamide could not be recovered, either in the urine or in the breath, during the 72-hr period of the experiment. This suggests that acetamide, may undergo further metabolism to get incorporated into the acetate pool. This would result in very slow elimination of the remaining activity as /sup 14/CO/sub 2/ or as another unknown metabolite.

Research Organization:
Univ. of Houston, TX
OSTI ID:
5765777
Journal Information:
Drug Metab. Dispos.; (United States), Vol. 12:4
Country of Publication:
United States
Language:
English